Received COPP-WHO and accreditation certificate of foreign drug manufacture from Japan
IOL Chemicals and Pharmaceuticals Limited (IOLCP), one of the largest producers of organic chemicals and bulk drugs in India, has announced that it has received coveted certifications for exports of its pharma product, Ibuprofen, to various countries. These certifications include
- Accreditation Certificate of Foreign Drug Manufacture from Ministry of Health, Labor and Welfare, Japan, and
- Certificate of Pharmaceutical Product (COPP) from Director, Health & Family Welfare, Punjab conforming to the WHO guidelines, which certifies IOLCP’s Ibuprofen as an Active Pharmaceuticals Ingredient (API) fit to be exported to other countries from India.
The company has also received DMF acknowledgment for Ibuprofen from Food & Drug Administration, USA. IOLCP already exports its various products to many countries across the world including Argentina, Brazil, China, Denmark, Germany, Singapore, Hong Kong, Kenya, Malaysia, Peru, Egypt etc.
Mr. R K Thukral, Executive Director, IOL Chemicals and Pharmaceuticals Limited, said, “We are extremely delighted to receive these certifications as they will open up a whole new market of opportunities for us. As one of India’s leading manufacturers of bulk drugs, we aim to capitalize upon the opportunities and strengthen our export revenues further by exporting ibuprofen to many pharmaceutical markets abroad.”
The production capacity of Ibuprofen has been the stronghold of IOLCP’s pharmaceutical operations and the company has recently boosted its Ibuprofen plant capacity to 3600 TPA from 1800 TPA. The company further aims to expand the capacity to 6000 TPA. IOLCP’s expansion plans worth Rs.216 crore include capacity expansion for its various product lines, forward and backward integration and increase in cogeneration of power.
As part of its Backward Integration plan, the company is going to commence a new plant of Isobutyl Benzene (IBB) having annual capacity of 6000 MT to ensure ready availability of the most important raw material of Ibuprofen. The production in this plant is expected to commence in next quarter.
More From This Section
“We are working at an enormous pace to increase our manufacturing capacity to keep up with the burgeoning demand of our most successful pharmaceutical product, ibuprofen, which is used to reduce fever and treat pain or inflammation caused by many ailments such as headache, toothache, back pain, arthritis, menstrual cramps, or minor injuries,” added Mr. Thukral.
As part of its Forward Integration plan, IOLCP will add two more products i.e. Mono Chloro Acetic Acid(MCA) with a capacity of 6600 TPA and Acetyl Chloride with a capacity of 4800 TPA, using Acetic Acid and Acetic Anhydride as a raw material.
IOLCP also plans to increase the production capacity of Acetic Acid from 50000 TPA to 75000 TPA, Ethyl Acetate from 33000 TPA to 36000 TPA and that of Acetic Anhydride from 12000 TPA to 18000 TPA.
IOLCP has recently been once again awarded the most prestigious National Energy Conservation Award 2008 (second prize in chemical sector) for its ongoing efforts towards new technology implementation to conserve precious energy resources. The company won this award consecutively for the previous three years—2005, 2006 and 2007, as well.
Apart from the facts that IOLCP currently co-generates around 4 MW of power which is being upgraded to 17 MW and its energy conservation initiatives, IOLCP is also actively involved in protection and preservation of the environment in and around its manufacturing units. The company’s environmental policy includes sustained efforts towards minimizing adverse environmental impact by controlling emission, effluents and waste generation at its manufacturing units in order to prevent pollution and reduce its carbon footprint.
At IOLCP, there is constant quest for Innovation in products and processes. Driven by an intensive R&D program manned by a highly trained and competent team, this drive for innovation has led the company to develop and enhance its capabilities over the years. Equipped with cutting edge tools and facilities, IOLCP’s research and development process is managed by a highly trained and motivated team of experts. IOLCP’s vast capabilities in research and breakthrough developments have allowed the company to undertake in-house development of technologies required in its manufacturing process.
About IOL Chemicals and Pharmaceuticals Limited
Established in 1986, IOLCP, a public-listed company (BSE), is one of the largest manufacturers of industrial chemicals and bulk drugs with presence in over 52 countries across the world. IOLCP manufactures and supplies Industrial Chemicals and Bulk Drugs for use in various pharmaceutical, Textile, Packaging, Lamination, Pesticides, Food processing applications. Its product portfolio includes industrial organic chemicals such as acetic acid, glacial acetic acid, ethyl acetate, acetic anhydride and bulk drugs like ibuprofen.
The turnover of IOLCP in the year 2007-2008 was Rs.361.35 crore and the company is currently in a phase of expansion with an investment outlay of Rs. 216 crore which would include capacity expansion for its various product lines, forward and backward integration and increase in cogeneration of power.
IOLCP's overseas customers are spread out across several countries including Argentina, Brazil, China, Denmark, Germany, Singapore, Hong Kong, Kenya, Malaysia, Peru, Egypt and many others. The company has strong business relationships with a number of prestigious clients such as Ranbaxy Labs, Dr Reddy, DS Group, CIPLA, Uflex Industries, ITC Limited, ICI Paints, Asian Paints, Pidilite, Rallis India, Hindustan Polymide, Gujarat Super Phosphate, and Avon Organics Ltd. etc. For more information on IOLCP, please visit http://www.iolcp.com